Eptinezumab is a fully-humanized IgG1 antibody manufactured using yeast (Pichia pastoris) and developed by Lundbeck Seattle Biopharmaceuticals.
Eptinezumab has been specifically designed to bind to both alpha and beta forms of the human calcitonin gene-related peptide (CGRP).8,1,2,3 It was approved by the FDA in February 2020 for the preventive treatment of migraine headaches in adults.
Applications:Suitable for use in ELISA and SDS-PAGE.
Other applications not tested.
Recommended Dilution:Optimal dilutions to be determined by the researcher.
Storage and Stability:May be stored at 4℃ for short-term only.
Aliquot to avoid repeated freezing and thawing.
Store at -20℃.
Aliquots are stable for 12 months after receipt.
For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
仕様
Size：100ug
抗体種類：Mab
宿主：human
Grade：Highly Purified
Purity：≥95%
Form：Supplied as a liquid in PBS, pH 7.5.
Specificity：Recognizes Eptinezumab (CALCA/CALCB).
Isotype：IgG1,k
Calc Applications Abbrev：E
Immunogen：Recombinant protein corresponding to humanized CALCA/CALCB [Homo sapiens], expressed in CHO cells.
